Results 241 to 250 of about 11,447,845 (407)
Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon +4 more
wiley +1 more source
A Dose-Aware Model for Revealing Dose-Risk Relationship of Drug-Drug Interaction. [PDF]
Shi Y +8 more
europepmc +1 more source
Interplay between RNA‐protein interactions and RNA structures in gene regulation
Methodological advances in mapping transcriptome‐wide RNA‐protein interactions and RNA structures have started to uncover the potential of RNP conformations in gene regulation. Competing RNA–RNA, RNA‐protein and protein–protein interactions shape the compaction and function of RNPs throughout their lifetime and may provide novel therapeutic targets in ...
Jenni Rapakko +2 more
wiley +1 more source
UGT2B7-mediated drug-drug interaction between cannabinoids and hydromorphone. [PDF]
Coates S, Bardhi K, Zhao M, Lazarus P.
europepmc +1 more source
Representation of the suggested mode of action of lactoferrin (Lf) in nonsmall cell lung cancer (NSCLC) A549 cells. Lf induces activation of caspase‐3 by activating p53 and AChE leading to decreased ACh concentrations. In turn, ACh signaling leads to activation of VEGF and AKT and blocking of caspase‐3.
Stuti Goel +9 more
wiley +1 more source
Drug-Drug Interaction Management Among Pharmacists in Jordan: A National Comparative Survey. [PDF]
Abdel-Qader DH +5 more
europepmc +1 more source
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee +3 more
wiley +1 more source
Prescribing Practices, Polypharmacy, and Drug Interaction Risks in Anticoagulant Therapy: Insights from a Secondary Care Hospital. [PDF]
Shareef J +4 more
europepmc +1 more source
Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays
We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul +3 more
wiley +1 more source

